Cargando…

Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study

INTRODUCTION: Previous studies have shown that traditional risk factors such as hypercholesterolemia and hypertension account for only a small proportion of the dramatically increased risk of atherosclerotic coronary artery disease (CAD) in systemic lupus erythematosus (SLE). However, in these studi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nikpour, Mandana, Urowitz, Murray B, Ibanez, Dominique, Harvey, Paula J, Gladman, Dafna D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308087/ https://www.ncbi.nlm.nih.gov/pubmed/21955652 http://dx.doi.org/10.1186/ar3473

Ejemplares similares

Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study
por: Nikpour, Mandana, et al.
Publicado: (2010)

Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies
por: Tselios, Konstantinos, et al.
Publicado: (2016)

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
por: Tselios, Konstantinos, et al.
Publicado: (2021)

Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease
por: Al Rayes, Hanan, et al.
Publicado: (2017)

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
por: Sivakumaran, Jagan, et al.
Publicado: (2021)

Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus
por: Medina-Rosas, Jorge, et al.
Publicado: (2015)

The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus
por: Mai, Lloyd, et al.
Publicado: (2021)

Development validation and reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50
por: Touma, Z, et al.
Publicado: (2012)

Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study
por: Ky, Christa, et al.
Publicado: (2015)

Radiofrequency Ablation of the Atherosclerotic Plaque: a Proof of Concept Study in an Atherosclerotic Model
por: Ellenbroek, Guilielmus H.J.M., et al.
Publicado: (2017)

Nonlymphoma hematological malignancies in systemic lupus erythematosus
por: Lu, M, et al.
Publicado: (2012)

Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis
por: Whittall-Garcia, Laura, et al.
Publicado: (2022)

Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study
por: Urowitz, Murray B, et al.
Publicado: (2015)

A Novel Pool of Microparticle Cholesterol Is Elevated in Rheumatoid Arthritis but Not in Systemic Lupus Erythematosus Patients
por: Hu, Shuaishuai, et al.
Publicado: (2020)

Lung cancer in systemic lupus erythematosus
por: Kale, M, et al.
Publicado: (2012)

Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus
por: Connelly, K. L., et al.
Publicado: (2016)

Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study
por: Sreedharan, Sidha, et al.
Publicado: (2022)

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
por: Koelmeyer, Rachel, et al.
Publicado: (2020)

Current concepts of photosensitivity in cutaneous lupus erythematosus
por: Klein, Benjamin, et al.
Publicado: (2022)

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
por: Emamikia, Sharzad, et al.
Publicado: (2022)

Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis
por: Keyes, Emily, et al.
Publicado: (2021)

Association Between Cumulative Exposure to Increased Low-Density Lipoprotein Cholesterol and the Prevalence of Asymptomatic Intracranial Atherosclerotic Stenosis
por: Kang, Kaijiang, et al.
Publicado: (2020)

HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus
por: García-González, María, et al.
Publicado: (2023)

Elevated serum cholesterol levels are associated with proteinuria over 0.5 g/day in premenopausal women with systemic lupus erythematosus
por: Liu, Haijun, et al.
Publicado: (2022)

Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus
por: Fetter, Tanja, et al.
Publicado: (2022)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
por: Furie, Richard, et al.
Publicado: (2014)

Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data
por: Clowse, Megan E B, et al.
Publicado: (2022)

Non-Traditional Pro-Inflammatory and Pro-Atherosclerotic Risk Factors Related to Systemic Lupus Erythematosus
por: Richter, Patricia, et al.
Publicado: (2022)

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
por: Hanly, John G., et al.
Publicado: (2019)

Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
por: Parker, Ben, et al.
Publicado: (2013)

Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease: a prospective community-based study
por: Guan, Xu-Min, et al.
Publicado: (2023)

Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria
por: van Vollenhoven, Ronald, et al.
Publicado: (2022)

State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus
por: Zhao, Megan, et al.
Publicado: (2023)

Elevated titers of anti-ribosomal-P antibodies in systemic lupus erythematosus
por: Zandman-Goddard, G, et al.
Publicado: (2005)

Serum Interleukin-34 Levels Are Elevated in Patients with Systemic Lupus Erythematosus
por: Wang, Hongxu, et al.
Publicado: (2016)

Elevated plasma midkine and pleiotrophin levels in patients with systemic lupus erythematosus
por: Wu, Guo-Cui, et al.
Publicado: (2016)

Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort
por: Yap, K S, et al.
Publicado: (2015)

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
por: Furie, Richard A, et al.
Publicado: (2021)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3jg49md75617bvara5kg7vhotg